About the book
Many viruses have periodically emerged worldwide with devastating economic, social, and health effects. Coronavirus disease 2019 (COVID-19) is the latest global pandemic virus that has lamed the whole world a heavy burden not only on the public healthcare system but also on the worldwide economy, education, and daily human life.
There is a scarce of antiviral drugs available in the market for therapy. Many pieces of research and new analytical techniques have unraveled the event and progression of a virus infection. Nowadays there's an honest understanding of the multiplication cycle of viruses, including the human immunodeficiency virus. The currently available antiviral drugs are presented arranged by their mode of action which will be understood by the multiplication cycle of the virus. The antiviral therapeutic area continues to rapidly generate meaningful new chemical entities; for instance, for HIV alone 25 drugs are approved, and within the next few years many drugs and single-tablet regimens will be approved for the treatment of hepatitis C virus infection. The increasing success within the antiviral area might be thanks to targeting drugs at "non-self" genomes and to the patient population that's tolerant of manageable side effects and adaptable to inconvenient dosing.
At present, no treatment is available, apart from symptomatic interventions, but many vaccine- and drug-based approaches are being investigated worldwide and it is too early to judge their efficacy and safety.
This book will aim to present new successful strategies; e.g artificial intelligence and better utilization of old/existing/available drugs for developing molecules with new pharmacological/therapeutic indications, high margin of safety, and reasonable economic cost.
Artificial intelligence (AI) techniques; e.g machine learning (ML) and deep learning (DL) have shown promising results in healthcare through its decision-making by analyzing the huge available perplexing data to provide rapid and reliable clinical decisions in diagnostic uncertainty or complex cases with high accuracy.
Aimed at medicinal chemists and emerging drug discovery scientists, this book will be organized based upon diverse approaches for the discovery and optimization of initial lead compounds. This book will focus on capturing tactical aspects of problem-solving in antiviral design, an approach that holds special appeal for those engaged in antiviral development, but also appeals to the broader medicinal chemistry community supported its specialization in tactical aspects of drug design.